Thrombi contains electropositive patches at opposite poles of the molecule which represent potential exosites for the binding of macromolecular ligands. The Thrombin is a critical regulator of hemostasis and is an important target for anticoagulant therapy in thromboembolic disorders. The principal anticoagulant drug for the treatment of acute thrombosis is heparin, a glycosaminoglycan that catalyzes the inhibition of thrombin and other serine proteases by the serpin (serine protease inhibitor) antithrombin III (ATIII) (1). Endogenous glycosaminoglycans may regulate thrombin by a similar mechanism (2). The inhibition of thrombin by ATIII is a two-step process in which an initial, reversible complex is converted to a stable ATIII-thrombin complex in a first-order reaction. Heparin increases the affinity of the initial complex by nearly three orders of magnitude (3). The kinetics of inhibition are consistent with binding of both inhibitor and protease to heparin in a template fashion. In contrast to the inhibition of factor Xa, heparin-induced conformational change in ATIII contributes little to the acceleration of thrombin inhibition (4). Because heparin binds with higher affinity to ATIII than to thrombin, inhibition proceeds mainly through the interaction of ATIII-heparin complexes with free thrombin (5). Thrombin-heparin binding appears to be predominantly electrostatic, involving at least five ionic interactions. Thrombin does not require a specific heparin oligosaccharide sequence but interacts with relatively nonspecific sites approximately three disaccharides in length, with an intrinsic Kd of 5-10 pM (6).
Thrombin is a critical regulator of hemostasis and is an important target for anticoagulant therapy in thromboembolic disorders. The principal anticoagulant drug for the treatment of acute thrombosis is heparin, a glycosaminoglycan that catalyzes the inhibition of thrombin and other serine proteases by the serpin (serine protease inhibitor) antithrombin III (ATIII) (1) . Endogenous glycosaminoglycans may regulate thrombin by a similar mechanism (2) .
The inhibition of thrombin by ATIII is a two-step process in which an initial, reversible complex is converted to a stable ATIII-thrombin complex in a first-order reaction. Heparin increases the affinity of the initial complex by nearly three orders of magnitude (3) . The kinetics of inhibition are consistent with binding of both inhibitor and protease to heparin in a template fashion. In contrast to the inhibition of factor Xa, heparin-induced conformational change in ATIII contributes little to the acceleration of thrombin inhibition (4) . Because heparin binds with higher affinity to ATIII than to thrombin, inhibition proceeds mainly through the interaction of ATIII-heparin complexes with free thrombin (5) . Thrombin-heparin binding appears to be predominantly electrostatic, involving at least five ionic interactions. Thrombin does not require a specific heparin oligosaccharide sequence but interacts with relatively nonspecific sites approximately three disaccharides in length, with an intrinsic Kd of 5-10 pM (6) .
The surface of thrombin is characterized by two large electropositive patches at opposite poles of the molecule which represent potential exosites for the binding of negatively charged glycosaminoglycan ligands (7) . The fibrin(ogen) recognition site, or anion-binding exosite I, is located in a region suitable for binding amino acid residues on the carboxyl side of the scissile bond of thrombin substrates (7) . Exosite I contributes to the unique specificity of thrombin, binding not only substrates such as fibrinogen (8, 9) and the thrombin receptor (10) but also cofactors such as thrombomodulin (9) and inhibitors such as heparin cofactor 11 (11) , hirudin (12) , and single-stranded DNA aptamers (13) . The opposing electropositive surface patch, anion-binding exosite II, consists of the carboxyl-terminal a-helix of the protease and portions of adjacent surface loops. The kringle 2 domain of prothrombin forms a noncovalent complex with thrombin by interacting with exosite I (14) , indicating that this exosite is not accessible in prothrombin. Upon activation to thrombin, kringle 2 dissociates and exosite II is exposed.
After activation to a-thrombin, no function has been demonstrated directly for anion-binding exosite II. Heparin protects lysine residues (Lys-174 and Lys-252) within exosite II from chemical modification, suggesting that this region may contain a heparin-binding site (15) . Furthermore, the amphipathic carboxyl-terminal a-helix of thrombin contains a structural motif (-B-X-B-B-, where B is a basic residue) that resembles sequences found in other heparin-binding peptides and proteins (16) . However, other studies have suggested that exosite I may bind heparin (17) . Definition of the structure of the heparin-binding site may lead to improvements in the design of glycosaminoglycan anticoagulants and would permit investigation of other potential roles for exosite II in thrombin function.
We employed mutagenesis to characterize a functional heparin-binding site on thrombin. Basic amino acid residues in anion-binding exosite II constitute part of this site, based on the ability of mutations to selectively decrease both the affinity of thrombin for heparin-agarose and the rate of heparin-dependent inhibition by ATHI. The heparin-binding site extends from the carboxyl-terminal a-helix towards the "north rim" of the active site, which may facilitate interaction with ATIII. Anion-binding exosite II therefore contains a second functional binding site on thrombin that is important for interaction with macromolecular ligands. (7) . Plasmid pCMVPT, containing a human prothrombin cDNA inserted in the pCMV vector, and mutant plasmids pR68E and pK1S4E were described previously (9, 19) . Plasmids pR89E, pK174E, pR245E, pK247E, pK248E, and pK252E were constructed to have the indicated mutations (e.g., R89E = Arg-89 --Glu) by mutagenesis of pCMVPI using the polymerase chain reaction (9) . Amino acid substitutions were made by changing the first nucleotide in the codon AAG (Lys) to GAG (Glu) or the entire codon CGC (Arg) to GAG (Glu). DNA sequence was confirmed for all segments derived from polymerase chain reactions.
MATERIALS AND METHODS
Recombinant Thrombins. CV-1 (wild type, R68E, K154E, K174E, and K252E) or BHK (R89E, R245E, K247E, and K248E) cell lines were obtained by cotransfection ofplasmids with pSV2neo (20) and selection with G418 (9). Prothrombins were expressed at a0.5 ug/ml of conditioned medium (11) .
Recombinant prothrombins were partially purified from conditioned media by precipitation with barium sulfate and chromatography on DEAE-Sephacel (11). Activation to thrombin was performed by addition of 0.01 vol of 2.8 mg/ml Oxyuranus scutellatus venom (Sigma) (21) preabsorbed with Amberlite CG-50 (Sigma) (%1:5 venom-to-substrate ratio, wt/wt), 0.01 vol of rabbit brain cephalin (Sigma), CaCl2 to 5 mM, and incubation at 37°C for 60 min. Thrombin was purified to homogeneity by ion-exchange chromatography on Amberlite CG-50 (22) and quantitated by absorbance at 280 nm, using an extinction coefficient (eo.1%) of 1.83 (23) . Purity was confirmed by SDS/10%o polyacrylamide gel electrophoresis (24) and silver staining (Integrated Separation Systems, Natick, MA). Recombinant thrombin active sites were quantitated by titration with hirudin (25, 26 The recombinant hirudin standard was calibrated with plasma thrombin quantitated by active site titration with p-nitrophenylguanidinobenzoate (27) .
Determination of Mlchaelis Constant (K.) for S-2238. The value of Km for the chromogenic substrate S-2238 was determined from progress curves by using the programs KINSIM (28) and FITSIM (29) as described previously (11) . Assay conditions were the same as for the serpin inhibition assays: 0.15 M NaCl/0.02 M Tris HCl, pH 7.4/0.1% polyethylene glycol of average Mr = 8000 (PEG-8000) (TS/PEG buffer) at room temperature.
Thrombin Inhibition by ATIII. Assays in the absence of heparin were performed at room temperature in TS/PEG buffer under pseudo-first-order conditions (150 nM ATIII and 5 nM thrombin). Samples were removed for quantitation of residual thrombin by the rate of hydrolysis of S-2238, and the values for the apparent first-order rate constant (k') and the second-order rate constant (k2) ofinhibition were determined by nonlinear least squares regression as described (11) .
For inhibition in the presence ofheparin, thrombins with k2 EDTA/0.1% PEG-8000 were applied at 0.5 ml/min to a 1.0-ml heparin-Sepharose FPLC column (Pharmacia) equilibrated in the same buffer. The column was eluted at 0.5 ml/min with 5 ml of starting buffer followed by a 40-ml gradient of 0.1-1.0 M NaCl. Thrombin was detected by absorbance at 280 nm and confirmed either by fibrinogen clotting assays or by Western blotting with polyclonal rabbit anti-thrombin antibody.
Fibrinogen Clotting Activity. Active-site titrated thrombins were assayed for fibrinogen clotting activity in a purified thrombin time assay. Dilutions of thrombin were incubated in 200 p1 of 150 mM NaCl/10 mM CaCl2/10 mM imidazole HCl, pH 7.4/6.6% PEG-8000 in cuvettes at 370C. The assay was initiated by addition of 50 ul of human fibrinogen (KabiVitrum) at 2 mg/ml and the time to clot formation was measured with a fibrometer. Clotting times were converted to National Institutes of Health thrombin units (NIH U) by comparison with a standard thrombin preparation (Sigma).
RESULTS
Expression ofRecombinant Thrombins. Because the thrombin-heparin interaction is mainly electrostatic, basic amino acid residues on the thrombin surface were targeted for substitution by glutamic acid. Single amino acid substitutions of glutamic acid for lysine or arginine were constructed in both anion-binding exosite I (R68E, K154E) and the proposed heparin-binding site within anion-binding exosite II (R89E, K174E, R245E, K247E, K248E, and K252E) (Fig. 1) . These substitutions included the putative heparin binding motif (Arg-Xaa-Lys-Lys, residues 245-248) in the carboxylterminal a-helix (16) . The mutations in exosite I provided controls for the effects of similar mutations in exosite II. Recombinant prothrombins were expressed in CV-1 or BHK cell lines and activated to thrombin, and the thrombins were purified to homogeneity. Recombinant thrombins had electrophoretic mobility similar to plasma-derived thrombin under nonreducing conditions (Fig. 2) . Thrombins expressed in CV-1 cells migrated slightly faster than plasma-derived thrombin due to differences in glycosylation (data not shown). No degraded forms of thrombin were detected upon gel electrophoresis after reduction (data not shown).
Recombinant thrombins were quantitated by active-site titration with hirudin and then characterized enzymatically ( Table 1) . The values of Km and kt for S-2238 hydrolysis for all of the mutant enzymes were similar to those of plasmaderived and wild-type recombinant thrombin, suggesting that the S1 substrate-binding pocket and active site mechanism were intact. Furthermore, except for thrombins R68E and K174E, all recombinant thrombins displayed fibrinogen clotting activity similar to plasma-derived thrombin (Table 1) . Clotting activity provides an important test of tertiary structure, as interaction of thrombin with fibrinogen involves the apolar binding site, the S1 specificity pocket, the catalytic triad, and anion-binding exosite 1 (7, 31) . The mutation R68E disrupts a site in anion-binding exosite I that is important for fibrinogen recognition and profoundly reduces clotting ac- Affinity for heparin was assessed by a NaCl gradient elution from heparin-agarose. Wild-type thrombin eluted at =0.60 M NaCl, and only minor differences in elution position were observed for thrombins R68E, K154E, and K174E (Fig. 3A) . Thus, mutations R68E and K154E in anion-binding exosite I and K174E in anion-binding exosite II do not significantly affect the affinity of thrombin for heparin. However, other mutations within anion-binding exosite II decreased the affinity of thrombin for heparin-agarose: thrombin K247E was eluted at 0.52 M NaCl, thrombins R245E and K252E were eluted at P0.45 M NaCl, and thrombins R89E and K248E were eluted at 0.39 M NaCl (Fig. 3B) Proc. NaM Acad. Sci. USA 91 (1994) Inhibition assays were performed in the absence or presence (1 unit/ml) of heparin. The values for second-order rate constants (k2) ofinhibition by ATEI are expressed as the mean ± SD ofthree or more determinations. The concentration of NaCl at the midpoint of elution from heparin-agarose (Fig. 3) is indicated in the last column.
for heparin-agarose also did not significantly affect the rate of inhibition by ATHI plus heparin.
DISCUSSION
The clusters of basic amino acid residues at opposite poles of thrombin account for many of the unique properties of this serine protease (7) . The functions of anion-binding exosite I have been studied extensively (8) (9) (10) (11) (12) (13) . We now have defined a functional heparin-binding site within the electropositive surface of anion-binding exosite II.
Specific mutations within anion-binding exosite II decreased both the affinity for heparin-agarose and the rate of inhibition by ATIII plus heparin, demonstrating the importance of these basic residues for heparin binding. Despite marked reductions in heparin-dependent inhibition rates only small differences in heparin-independent rates were observed, demonstrating that the interaction of ATIH with the catalytic center of thrombin was not disrupted by these mutations. Similar mutations in anion-binding exosite I (R68E, K154E) or at the periphery of anion-binding exosite II (K174E) did not affect heparin affinity or heparindependent inhibition rates. These results are consistent with our previous report that several additional mutations in anion-binding exosite I have no effect on the rate ofinhibition by ATIII plus heparin (18) . Thus, the effects of mutations in exosite II were not due simply to changes in the total charge of thrombin.
The magnitude ofthe effect ofspecific mutations on affinity for heparin-agarose correlated with the amount of reduction in heparin-dependent inhibition rates. Although an additional effect on the rate of conversion from reversible to stable complex cannot be excluded, this correlation suggests that these mutations decrease the affinity of thrombin for both heparin and heparin-ATHI. Thus, these results support a template mechanism for thrombin inhibition by ATIII plus heparin (4) .
In the absence of conformational change, the electrostatic contribution of amino acid side chains to heparin binding should decline with increasing distance from the binding site. The effect ofmutations on binding can therefore delineate the extent of this site. Amino acid residues 243-256 near the carboxyl terminus of thrombin form an amphipathic a-helix in which the side chains ofR245, K248, and K252 extend into the solvent, as does the side chain of R89E located on an adjacent surface loop (Fig. 4) . All of these basic residues contribute to heparin binding. The side chain of K247, however, extends along the surface away from K248, and this spatial relationship accounts for the minimal contribution of K247 to heparin binding despite its proximity to the binding site. The side chain of K174 (located on an additional surface loop) does not make a significant contribution to heparin binding, despite the observation that heparin protects this residue from chemical modification (15) . Depending on the orientation of the heparin, other residues that contribute to binding could include H87(91) (buried below R89), R98(101), R123(126), and the more distant R93(97) and R180(175) (Fig.  4) . Interaction of heparin with one or more of these residues would be consistent with the prediction that thrombin binds to heparin by five or six ionic contacts (6) .
The heparin-binding site appears to be large enough to accommodate at least two disaccharide units (-17 A) (32) . The surface loop containing R89 and R93 is located near the "north rim" of the active site cleft (7) . On the basis of molecular modeling, the homologous surface loop in factor IX is proposed to participate in binding to ATIII (33) . Thus, the heparin-binding site may be adjacent to amino acid residues that interact with ATIII, which may facilitate docking of the protease with ATIII bound to heparin.
The electrostatic nature of thrombin binding to heparin suggests that it does not involve specific interactions with the glycosaminoglycan backbone (6). This does not exclude a preference for a particular spatial arrangement of ionic interactions, but does suggest that the binding site may not be specific for heparin. Heparin is structurally heterogeneous due to incomplete epimerization and sulfation (32) . A comparison among mutant thrombins for binding to different glycosaminoglycans could therefore indicate the range of structures that can bind with high affinity and interact with specific amino acid side chains. Binding to dermatan sulfate is of particular interest, because dermatan sulfate catalyzes thrombin inhibition by heparin cofactor 11 through a ternary complex similar to that employed by ATIII plus heparin (34) .
The accessibility of anion-binding exosite II may be regulated during prothrombin activation. In the noncovalent complex of thrombin and the kringle-2 fragient of prothrombin, kringle-2 makes contacts of less than 4 A with R89(93), R93(97), R98(101), and R180(175) and appears to sterically occlude the heparin-binding site (14) . Conservation of the cleavage site between fiagments F1 and F2 (containing the kringle-2 domain) of prothrombin suggests a potential role for intermediates that have an available anion-binding exosite I but a sterically hindered exosite 1 (35, 36) . The accessibility of exosite II may determine the susceptibility of thrombin to inhibition by ATIII in vivo. Heparan sulfate proteoglycans on the surface of endothelial cells possess significant anticoagulant activity and can accelerate the inhibition of thrombin by ATIII in situ (2) . Thus, mutations in the heparin-binding site could contribute to an inherited predisposition to thrombosis. Exosite II may also be important for localizing thrombin to specific sites in the endothelium (37) or extracellular matrix (38) while preserving accessibility of the active site and anion-binding exosite I to substrates and other ligands. Thrombin localized to extracellular sites by exosite II could be important for stimulating cellular responses involved in wound healing, inflammation, and atherosclerosis (39 
